ArticleLancet (London, England)2017

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.

Martin J van den Bent et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.